Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Baxter
Mallinckrodt
Boehringer Ingelheim
McKesson

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR DABRAFENIB MESYLATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Dabrafenib Mesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01902173 ↗ Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting GlaxoSmithKline Phase 1/Phase 2 2013-07-19 This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT01902173 ↗ Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting Novartis Pharmaceuticals Phase 1/Phase 2 2013-07-19 This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT01902173 ↗ Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2013-07-19 This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT01947023 ↗ Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery Active, not recruiting National Cancer Institute (NCI) Phase 1 2013-08-29 This phase I trial studies the side effects and best dose of lapatinib when given together with dabrafenib in treating patients with thyroid cancer that cannot be removed by surgery and has not responded to previous treatment (refractory). Dabrafenib and lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02196181 ↗ Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Active, not recruiting National Cancer Institute (NCI) Phase 2 2014-07-22 This phase II trial studies how well dabrafenib and trametinib work in treating patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02224781 ↗ Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Active, not recruiting National Cancer Institute (NCI) Phase 3 2015-07-13 This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dabrafenib Mesylate

Condition Name

Condition Name for Dabrafenib Mesylate
Intervention Trials
Recurrent Melanoma 4
Unresectable Melanoma 3
Metastatic Melanoma 3
Stage IIIC Cutaneous Melanoma AJCC v7 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dabrafenib Mesylate
Intervention Trials
Melanoma 7
Skin Neoplasms 6
Neoplasms 5
Glioma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dabrafenib Mesylate

Trials by Country

Trials by Country for Dabrafenib Mesylate
Location Trials
United States 210
Puerto Rico 2
Korea, Republic of 1
Guam 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dabrafenib Mesylate
Location Trials
Pennsylvania 8
Ohio 6
California 6
Colorado 6
Maryland 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dabrafenib Mesylate

Clinical Trial Phase

Clinical Trial Phase for Dabrafenib Mesylate
Clinical Trial Phase Trials
Phase 3 1
Phase 2 9
Phase 1/Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dabrafenib Mesylate
Clinical Trial Phase Trials
Active, not recruiting 6
Recruiting 4
Completed 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dabrafenib Mesylate

Sponsor Name

Sponsor Name for Dabrafenib Mesylate
Sponsor Trials
National Cancer Institute (NCI) 10
Novartis Pharmaceuticals 1
National Human Genome Research Institute (NHGRI) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dabrafenib Mesylate
Sponsor Trials
NIH 11
Other 5
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
AstraZeneca
Moodys
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.